Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.74, $0.45 worse than the analyst estimate of $1.19. Revenue for the quarter came in at $38.2 million versus the consensus estimate of $40.34 million.

GUIDANCE:

Ligand Pharma sees FY2017 EPS of $2.70.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.